Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.

Abstract

Thrombolytic efficacy of lonomin V (LV), a protein isolated from Lonomia achelous caterpillars haemolymph, administered either as a single intravenous bolus or as a continuous infusion, was evaluated in a rabbit jugular vein thrombosis model, and compared with those of single-chain tissue-type plasminogen activator (sct-PA) and two-chain urokinase-type plasminogen activator (tcu-PA). As a bolus LV, at doses of 100 000 IU/kg body weight (bw) produced an activator-induced thrombolysis (AIL) of 50.94% +/- 12.4 compared with 14.4% +/- 10.8 for tcu-PA at the same dose. As a continuous infusion at doses of 200 000 IU/kg bw LV produced an AIL of 45.8%, whereas sct-PA and tcu-PA produced an AIL of 69.9 and 33.7%, respectively. Fibrinogen, plasminogen and alpha-2-antiplasmin levels decreased significantly with the higher doses of LV, sct-PA, and tcu-PA. Factor XIII levels were significantly reduced in a dose-dependent manner only with LV. In conclusion, LV produces a dose-dependent thrombolysis in combination with a decrease in factor XIII activity.

• Authors: B Guerrero, C L Arocha-Piñango, M A Pinto, C A Müller, A G Gil San Juan, S Amorim, J Perales
• Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 12 Issue 7 Pg. 521-9 (Oct 2001) ISSN: 0957-5235 [Print] England
• PMID: 11685039 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anticoagulants
• Arthropod Venoms
• Fibrinolytic Agents
• alpha-2-Antiplasmin
• lonomin V
• Fibrinogen
• Plasminogen
• Factor XIII
• Tissue Plasminogen Activator
• Urokinase-Type Plasminogen Activator

Topics

• Animals
• Anticoagulants (administration & dosage, therapeutic use)
• Arthropod Venoms (administration & dosage, therapeutic use)
• Disease Models, Animal
• Factor XIII (analysis)
• Female
• Fibrinogen (analysis)
• Fibrinolytic Agents (administration & dosage, therapeutic use)
• Infusions, Intravenous
• Injections, Intravenous
• Jugular Veins
• Male
• Plasminogen (analysis)
• Rabbits
• Thrombolytic Therapy
• Tissue Plasminogen Activator (therapeutic use)
• Urokinase-Type Plasminogen Activator (therapeutic use)
• Venous Thrombosis (blood, drug therapy)
• alpha-2-Antiplasmin (analysis)